Evaluating the Therapeutic Potential of Antioxidants in Polyendocrine Metabolic Ovarian Syndrome (PMOS)-Associated Infertility Authors: Pramathes Das Mahapatra, Vidya Vishwanath Bhat, Noopur Ajaykumar Vyas, Shruti Dharmadhikari, Gaurav Puppalwar, Chintan Khandhedia, Amey Mane, Suyog Mehta Published: 2026 ABSTRACT AbstractIntroductionPolyendocrine Metabolic Ovarian syndrome (PMOS) formerly known as polycystic ovarian syndrome (PCOS) constitutes the most common endocrinopathy in women of reproductive age group. Evidence from numerous studies in PMOS patients suggests that antioxidants can modulate the ovarian microenvironment, promote folliculogenesis, and increase oocyte competence and yield. This review aims to summarize the existing clinical evidence regarding the application of antioxidants as adjunctive treatment options in the management of PMOS-related infertility.Materials and MethodsThis is a structured narrative review. A literature search (1990–2024) was conducted through PubMed, Google Scholar, and Cochrane Library to identify clinical trials evaluating the role of antioxidants specifically Coenzyme Q10 (CoQ10), N-acetylcysteine (NAC), melatonin, and astaxanthin (AST) in PMOS. Studies were identified and screened based on the predefined eligibility criteria. Inclusion criteria were full-text, English-language studies assessing antioxidant interventions in PMOS or related mechanisms; exclusions were reviews, meta-analyses, animal studies, duplicates, and non-English articles. Of 198 records screened, 28 studies met eligibility criteria and were included in this review.ResultsBased on the data included in our review, the available evidence suggests that CoQ10 enhances mitochondrial function and reduces oxidative stress (OS). It has been reported to increase clinical pregnancy rates, improve insulin sensitivity, sex hormone levels, and blood lipids. N-acetylcysteine scavenges free radicals, provides cysteine for glutathione synthesis, breaks disulfide linkages and reduces OS. It may help to improve pregnancy rates, insulin sensitivity, and metabolic parameters. Additionally, it enhances oocyte quality and supports detoxification. Astaxanthin is a potent antioxidant with anti-inflammatory properties and reduces OS, with the potential to improve the development of follicles and oocytes, insulin sensitivity, lipid parameters, and supports mitochondrial health and cellular function. Melatonin regulates circadian rhythms and reduces OS, helps restore regular menstrual cycles, reduces hyperandrogenism, may improve insulin sensitivity and enhance fertility.ConclusionAntioxidant supplementation may have a complementary role in improving reproductive outcomes in infertile women with PMOS. However, some uncertainty remains given the heterogeneity of the included studies and the limited number of trials for certain antioxidants. Further well-designed randomized controlled studies are required to establish definitive clinical benefit.Keywords: antioxidants, n-acetyl cysteine, astaxanthin, PMOS, melatonin, infertility, coenzyme Q10, polycystic ovary syndrome Introduction Polycystic ovary syndrome (PCOS) is a multifactorial endocrine–metabolic disorder, marked by ovulatory dysfunction, infertility, obesity, insulin resistance (IR), and polycystic ovarian morphology, defined as ovarian volume >10 mL and/or ≥10 follicles measuring 2–9 mm.1 PCOS constitutes the most common endocrinopathy of women of reproductive age group.2 Given that the term PCOS does not capture the condition’s multisystem pathophysiology, an important recent development in the international consensus recommendation was to rename PCOS as PMOS (Polyendocrine Metabolic Ovarian Syndrome). This terminology better reflects the condition by avoiding misleading references to ovarian cysts and accurately capturing the endocrine, metabolic, and ovarian dysfunction.3 PMOS is a complex endocrine condition, making its management a difficult and challenging task in every day clinical practice. While the exact mechanisms underlying the persistent ovulatory dysfunction and hyperandrogenaemia in PMOS remain unclear, the complexity and diversity of diagnostic criteria and therapeutic approaches have continued to expand since the original description of the condition by Stein and Leventhal in 1935.2 Globally, PMOS affects about 1.55 million women, contributing to an estimated 0.43 million disability-adjusted life years (DALYs). Compared with Western and other Asian populations, Indian women show a higher prevalence, ranging between 3.7% and 36%.4 Beyond physical manifestations, PMOS is associated with an elevated risk of psychological comorbidities—including mood, anxiety, and eating disorders—as well as impaired sexual well-being. Body image concerns may further contribute to social withdrawal and interpersonal difficulties.5 The pathophysiology of PMOS is driven by genetic, environmental, lifestyle, and gut microbiota factors that induce hormonal imbalance, hyperandrogenism, and Insulin Resistance, leading to clinical, reproductive, and metabolic complications.1 PMOS often begins at puberty, with fluctuating symptoms, and is primarily marked by hormonal imbalance, irregular cycles, elevated androgens, and polycystic ovarian morphology.6 Infertility mainly results from oligo-anovulation and poor oocyte quality, leading to reduced fertilization, implantation, and higher miscarriage rates. Abnormal endocrine, paracrine, and metabolic factors impair folliculogenesis and oocyte maturation, with PMOS accounting for ~90% of ovulatory dysfunction cases in infertility clinics.7 Managing PMOS effectively often requires addressing hormonal imbalances, menstrual irregularities and other complications associated with PMOS to improve fertility prospects. Numerous studies conducted on PMOS patients have demonstrated that antioxidants can improve an intraovarian milieu, support follicular maturation, and increase oocyte numbers. Additionally, they can improve lipid and glucose metabolism and support vascular endothelial cell function, which helps reduce adiposity and lower the risk of chronic complications, ultimately providing long-term benefits for patients.8 Despite its common occurrence, PMOS remains underdiagnosed and poorly managed, especially in relation to its associated symptoms and complications. Current treatments primarily focus on managing symptoms rather than addressing underlying hormonal imbalances and infertility challenges.2 With emerging evidence suggesting that antioxidants might offer therapeutic benefits,8 we conducted literature search to evaluate their potential as adjunctive treatments for improving fertility outcomes in PMOS patients. Although systematic reviews and meta-analyses have evaluated antioxidant supplementation in PMOS, these have often focused on individual agents or specific outcomes, and their findings remain heterogeneous and sometimes inconclusive. This review aims particularly to address the existing gap by providing a focused and integrative synthesis of antioxidants specifically Coenzyme Q10 (CoQ10), N-acetylcysteine (NAC), melatonin, and astaxanthin (AST) as adjunctive therapeutic agents that have been widely studied in the literature for their potential to improve reproductive outcomes in women with PMOS. Materials and Methods Literature Search and Selection Process Articles were searched using PubMed, Google Scholar, and the Cochrane Library from the year 1990 to 2024. The search was conducted with keywords including “Melatonin”, “Infertility”, “Coenzyme Q-10”, “Astaxanthin”, “N-acetyl cysteine”, “Polycystic Ovary Syndrome”, or “PMOS”. Titles and abstracts of all identified articles were screened for eligibility, and full-text papers that potentially fulfilled the inclusion criteria were retrieved. Inclusion criteria comprised studies evaluating antioxidants in the context of PCOS or related pathogenic mechanisms, full-text availability, English-language publication and clinical trial design. Exclusion criteria included studies not addressing antioxidant interventions, those unrelated to female infertility, non-English publications, review articles or meta-analyses, and studies involving animal models. After searching the databases, authors independently reviewed the titles and abstracts of 198 potentially relevant papers. Following this, full texts were examined for eligibility and relevance, leading to the exclusion of 162 articles due to irrelevance or insufficient relevance, ongoing study status, duplicate articles, non-English language, review articles and meta-analysis. Ultimately, 28 studies were selected for inclusion in the review. The entire study selection process used for identifying and screening eligible studies is summarized in Figure 1. Flowchart of the literature search and screening process for studies evaluating antioxidant therapy in PMOS. Selected papers were reviewed to ensure the accuracy of the extracted data. Key characteristics such as author names, publication year, study population, treatment methods, study design, PMOS model, and results were recorded. Oxidative Stress (OS) in PMOS Oxidative stress (OS) is an expression used to describe the imbalance between excessive formation of reactive oxygen species (ROS) and/or reactive nitrogen species and limited antioxidant defenses, which leads to various deleterious processes.9 The proposed pathophysiologic mechanisms through which oxidative stress contributes to PMOS development and progression are illustrated in Figure 2. Pathophysiologic role of oxidative stress in PMOS. Abbreviations: ROS, reactive oxygen species; LH, luteinizing hormone; FSH, follicle stimulating hormone; PCOS, polycystic ovarian syndrome; mtDNA, mitochondrial DNA. Genetic variability in gene coding for antioxidant enzymes has been shown to affect both the risk of PMOS and the metabolic characteristics of affected individuals.10 Malondialdehyde (MDA), a product of peroxidized polyunsaturated fatty acids, is commonly used as a biological marker for OS.11,12 According to a study, women with PMOS had higher than normal levels of MDA and C-reactive protein (CRP), which suggests that their OS status was increased.13 Additionally, PMOS patients often have high levels of MDA as well as reduced antioxidant indices such as low serum zinc levels and catalase activity, these effects are more prominent in those who also have IR and infertility.14 Total antioxidant status (TAOS) reflects the overall plasma antioxidant capacity, while protein carbonyls serve as markers of ROS-induced protein oxidation. Studies show that women with PMOS have reduced TAOS and elevated protein carbonyl levels, indicating oxidative stress and diminished antioxidant defense.15 Chattopadhayay et al examined 326 oocytes from 35 women with PMOS and 208 oocytes from 32 women with tubal infertility to evaluate the effect of follicular fluid OS on meiotic spindle formation in oocytes. They found that women with PMOS exhibited higher number of OS markers in their oocytes. Additionally, fertilization rates, embryo quality, and pregnancy rates were lower in women with PMOS compared to those with tubal infertility. The study concluded that high OS could negatively impact oocyte development, reducing fertilization potential and ultimately pregnancy rates.16 Moreover, ovarian reserve, oocyte quality, and placental growth can all be adversely affected by an imbalance between oxidants and antioxidants in the ovary.17,18 Overall, PMOS has a negative impact on ovarian function and reproductive outcomes due to increased ROS production and reduced antioxidant defences. Role of Antioxidants in PMOS Antioxidants not only improve oxidative stress and insulin resistance in PMOS but also lowers androgen levels, enhances the ovarian environment, and encourages follicular maturation. It has the potential to improve pregnancy outcomes when used with assisted reproductive technology and conventional ovulation-inducing regimens. Since dyslipidemia and endothelial dysfunction are early indicators of cardiovascular disease, antioxidants can control lipid metabolism and vascular endothelial cell function by reducing the incidence of chronic complications and improving the quality and psychological well-being of PMOS patients. Several antioxidants with substantial positive effects and low adverse reaction rates can alleviate symptoms, prevent long-term complications, or treat them. Antioxidant use in clinical settings should be encouraged after a thorough evaluation of each patient’s medical history and disease profile.8 Coenzyme Q10 (CoQ10) The existing clinical evidence strongly supports the significance of CoQ10 as an adjunctive intervention in women with PMOS and related infertility conditions. Across multiple randomized and placebo-controlled trials, CoQ10 has consistently demonstrated beneficial effects on ovarian response, hormonal balance, ovulation, and embryo quality. In a randomized controlled trial by Xu et al, women with PMOS and poor ovarian response who received CoQ10 (200 mg three times daily for 60 days) exhibited a notable enhancement in assisted reproductive outcomes, including an increased number of retrieved oocytes, improved fertilization rates, and a higher quantity of high-quality embryos.19 Similarly, Karamali and Gholizadeh demonstrated that 12 weeks of CoQ10 supplementation (100 mg/day) in women with PMOS significantly reduced androgen levels, oxidative stress markers, and clinical hirsutism, while increasing sex hormone–binding globulin and total antioxidant capacity, indicating an improvement in both endocrine and metabolic profiles.20 The reproductive benefits of CoQ10 are further supported by studies assessing ovulation induction. Jamal et al reported that incorporating CoQ10 with clomiphene citrate significantly improved the success rate of ovulation induction compared to clomiphene alone, suggesting a synergistic effect.21 In clomiphene-resistant PMOS patients, Refaeey et al found that CoQ10 supplementation led to a higher number of mature follicles, greater endometrial thickness, and improved clinical pregnancy rate compared with standard therapy alone.22 Furthermore, Ghasemzadeh et al demonstrated that CoQ10 administration in infertile women enhanced oocyte mitochondrial ATP production, increased fertilization rates, and reduced reactive oxygen species levels, reinforcing its role in enhancing oocyte bioenergetics and reducing oxidative stress.23 Ansam et al evaluated the impact of vitamin D3 and CoQ10 as supplementary treatments to clomiphene citrate. It was concluded that the supplementation of both vitamin D3 and CoQ10 resulted in notable reductions in luteinizing hormone (LH), the LH:FSH ratio, and AMH, while also increasing GSH which is an antioxidant marker. Furthermore, the intervention resulted in a substantial improvement in ovulation rates (75%), with a concomitant increase in pregnancy rates (15%), highlighting the potential clinical value of vitamin D and coenzyme Q10 supplementation in women with clomiphene-citrate–resistant PMOS.24 These findings provide convincing evidence that CoQ10 serves as a valuable therapeutic adjunct in the management of PMOS and infertility.24 A comprehensive summary of the relevant data is shown in Table 1. Table 1Evidence for Coenzyme Q-10AuthorStudy DesignKey Eligibility CriteriaInterventionSample SizeKey FindingsY. Xu et al (2018)19Randomized controlled trialPCOS with Poor ovarian responseTest arm: CoenzymeQ-10200 mg 3 times daily (for 60 days)Control arm: No treatment.186Women in CoQ10 group had increased number of retrieved oocytes (4, IQR 2–5), higher fertilization rate (67.49%) and more high-quality embryos (1, IQR 0–2); p < 0.05.Karamali and Gholizadeh (2022)20Double-blinded, placebo-controlled randomized clinical trialPCOSRandomized into groups receiving 100mg/day of CoQ10 (28 cases) or placebo (27 cases) for 12 weeks.55CoQ10 group exhibited a significant drop in total testosterone (p =.004), DHEAS (p <.001), hirsutism (p =.002) and MDA (p=001) levels in the serum, and a significant rise in SHBG (p <.001) and TAC (p <.001) levels in the serum than the placebo group.Jamal et al (2023)21Randomized StudyPCOSTest arm (CoQ10 plus Clomiphene citrate) andControl arm (Clomiphene citrate alone)136In CoQ10 plus Clomiphene citrate group, successful ovulation induction was noted in 16 (23.5%) patients, showing that with the addition of CoQ10, the chances of ovulation induction increased.El Refaeey et al (2014)22Randomized studyCC-resistant PCOSTest arms: CoQ10 (60 mg; starting oncycle day 2 and until the day of human chorionic gonadotrophin administration). and clomiphene citrate (150 mg/day; from cycle days 2–6)Control arm: Clomiphene Citrate (150 mg/day from cycle day 2 for 5 days)101Numbers of follicles >14 mm and ≥18 mm were significantly higher in the CoQ10 arm. Endometrial thickness on the day of human chorionic gonadotrophin was significantly greater in the CoQ10 group (65.9%) in the CoQ10 arm and 11/71 cycles (15.5%) in the control group. Clinical pregnancy rate was significantly higher in the CoQ10 arm versus the control arm (37.3%).Ghasemzadeh et al (2020)23Randomized, placebo-controlled trialsInfertileTest arm: Coenzyme Q10 capsule andControl arm: Placebo128Administering Q10 coenzyme significantly increased the number of fertilized oocytes and production of mitochondrial ATP of oocytes and simultaneously led to significant decrease in ROS levels of oocytes.Abbreviations: PCOS, polycystic ovarian syndrome; CoQ10, Coenzyme Q10; DHEAS, dehydroepiandrosterone sulfate; MDA, malondialdehyde; SHBG, sex hormone binding globulin; TAC, total antioxidant capacity. Evidence for Coenzyme Q-10 Abbreviations: PCOS, polycystic ovarian syndrome; CoQ10, Coenzyme Q10; DHEAS, dehydroepiandrosterone sulfate; MDA, malondialdehyde; SHBG, sex hormone binding globulin; TAC, total antioxidant capacity. N-Acetylcysteine (NAC) The available evidence from various randomized and prospective clinical studies suggest that N-acetylcysteine (NAC) offers beneficial metabolic, hormonal, and reproductive effects in women with PMOS. In a prospective comparative study by Kumari et al,25 NAC administered at 600 mg three times daily produced noteworthy reductions in fasting glucose and insulin levels compared to metformin. Additionally, there was a notable reduction in total testosterone levels, indicating that NAC may act as an alternative insulin-sensitizing agent in the management of PMOS. Similar improvements in metabolic and hormonal parameters, including reductions in LH/FSH ratio and glucose–insulin ratio, were reported by Ashok et al,26 who concluded that NAC to is as effective as metformin in improving menstrual irregularities and infertility parameters. Several randomized controlled trials have demonstrated that NAC enhances ovulation and pregnancy outcomes when combined with clomiphene citrate (CC). More information on the evidence is presented in Table 2. Humma et al27 showed that the addition of NAC to CC significantly increased endometrial thickness, ovulation rate, and pregnancy rate compared with CC alone. These findings were corroborated by Salehpour et al28 and Ghomian et al,29 who reported higher numbers of mature follicles, improved endometrial thickness, and increased ovulation and pregnancy rates in CC-treated PMOS patients receiving NAC. Maged et al30 further demonstrated that although ovulation rates per cycle were similar across treatment groups, CC combined with NAC resulted in a significantly higher pregnancy rate per patient and greater endometrial thickness compared with CC alone or CC plus metformin. Nemati et al31 stated that NAC led to greater reductions in fasting blood glucose and hirsutism compared with metformin, with both agents significantly improving pregnancy rates. Rizk et al32 demonstrated a marked improvement in ovulation and pregnancy rates when NAC was combined with CC, with no cases of ovarian hyperstimulation syndrome reported. Similarly, Nasr33 observed a substantial increase in ovulation and pregnancy rates with NAC compared to placebo in CC-resistant patients. Additionally, NAC has shown efficacy when combined with letrozole; Teimouri et al34 reported higher pregnancy rates in the NAC plus letrozole group compared with letrozole alone, indicating a positive role of NAC in enhancing fertility outcomes. Table 2Evidence for N-AcetylcysteineAuthorStudy DesignKey Eligibility CriteriaInterventionSample SizeKey FindingsKumari et al (2020)25Prospective, comparative studyInfertile with PCOSGroup M received metformin 500 mg three times a day.Group N received NAC, 600 mg three times a day.100Fasting glucose (103.6 ± 13.23 and 106.39 ± 10.88 respectively) and fasting insulin (24 ± 3.57 and 24.25 ± 3.11 respectively) were reduced in both groups significantly. Total testosterone was significantly reduced in Group N. NAC can be used as a substitute for insulin-sensitizing agent in treatment of PCOS.Humma et al (2016)27Randomized Placebo-controlled trialInfertility due to anovulation associated with PCOSTest arm Clomiphene Citrate (CC) 50mg/day for plus NAC 1.2g/d andControl arm Clomiphene Citrate (CC) 50mg/day only starting at day 3 – day 7 of the cycle90The mean endometrial thickness (8.2±1.1), ovulation rate (44.44%), and pregnancy rates (21%) were all significantly higher in the CC+NAC arm.Salehpour et al (2012)28Placebo-controlled double-blind randomized trialPCOSTest arm: CC 100 mg/d + NAC 1.2 g/dControl arm: CC + placeboDuration of intervention: 5 days starting at day 3 of the cycle.180In the group 1, the number of follicles >18 mm and mean endometrial thickness on the day of hCG administration were significantly higher (P=0.001). This group also had higher ovulation and pregnancy rates (P=0.02 and P=0.04, respectively).Ghomian et al (2018)29Blinded randomized controlled trialPCOSTest arm: 100 mg of clomiphene along with 1200 mg of NAC & Control arm: 100 mg of clomiphene was administered66NAC improves oxidative balance and insulin resistance and has shown beneficial effects in the treatment of infertility with PCOS by demonstrating pregnancy rates as [(21.2%) and (15.1%) in the intervention and control groups (P = 0.260)]Teimouri et al (2020)34Randomized control trialPCOSStudy arm:(5 mg letrozole + 1200mg NAC) and Control arm: (5mg letrozole alone)317The pregnancy rates were 14.6% in the intervention group and 7.5% in the control group. Additionally, follicles exceeding 18 mm were noted in the intervention group (47.5%) and the control group (60.4%), demonstrating the substantial impact of NAC on enhancing fertility in these patients.Nemati et al (2017)31Randomized controlled studyCC-resistant PCOSGroup 1 received 600 mg of NAC three times a day andGroup 2 received 500 mg of Metformin three times a day.108Significant reduction in hirsutism and FBS levels in NAC group compared to metformin group. Treatment with metformin and NAC significantly increases the pregnancy rated in CC-resistant PCOS women.Rizk et al (2005)32Placebo-controlled, double-blind randomized trialCC-resistant PCOSTest arm: NAC 1.2 g/d + CC 100 mg/dControl arm: Placebo + CC 100 mg/dDuration of intervention: 5 days starting at day 3 of the cycle.150The integration of CC and NAC led to a notable enhancement in both the ovulation rate (49.3% versus 1.3%) and the pregnancy rate (21.3% versus 0%) among women suffering from CC-resistant PCOS. There were no instances of OHSS reported in the NAC group; however, two cases of miscarriage were documented (12.5%).Maged et al (2015)30Randomized studyPCOSGroup 1: CC only andGroup 2: CC + 600 mg of NAC 2 times a day and Group 3: CC+ 500mg of metformin 3 times a day120There were no significant differences among the three study groups in ovulation occurrence, laterality, or pregnancy rate per cycle. However, Group II had a significantly higher pregnancy rate per patient (20%) compared to the other two groups (10%, p=0.05). Additionally, Group II had a significantly higher peak endometrial thickness (7.3 ± 1.1 mm) compared to the other two groups (5.4 ± 0.6 mm and 5.3 ± 0.6 mm).Nasr (2010)33Randomized double-blind placebo-controlled pilot studyCC-resistant PCOSTest arm: NAC 1.2 g/dControl arm: PlaceboDuration of intervention: 5 days starting at day 3 of the cycle for 12 consecutive cycles60A significant increase in both ovulation 87% and pregnancy rates 77% was observed in the NAC arm.Ashok et al (2018)26Prospective, Single-blinded randomized trialPCOSGroup A received metformin 500 mg three times a day andGroup B received N acetyl cysteine, 600 mg three times a day.100Hormonal parameters such as LH (12.21±4.67 and 10.36±3.61), FSH (7.19±1.48 and 6.58±1.51), oligomenorrhea, amenorrhea, and measurable reduction in infertility was noted It was also observed that LH/FSH ratio and glucose/insulin ratio (4.90±1.00 and 5.46±1.16 respectively) got reduced in both the groups.Abbreviations: PCOS, polycystic ovarian syndrome; NAC, N-acetylcysteine; LH, luteinizing hormone; FSH, follicle stimulating hormone; OHSS, ovarian hyperstimulation syndrome; hCG, Human Chorionic Gonadotropin; FBS, fasting blood sugar. Evidence for N-Acetylcysteine Abbreviations: PCOS, polycystic ovarian syndrome; NAC, N-acetylcysteine; LH, luteinizing hormone; FSH, follicle stimulating hormone; OHSS, ovarian hyperstimulation syndrome; hCG, Human Chorionic Gonadotropin; FBS, fasting blood sugar. Astaxanthin (AST) Findings from recent randomized controlled trials suggests that astaxanthin (AST) supplementation exerts beneficial antioxidant and reproductive effects in women with PMOS. In a double-blind, randomized, placebo-controlled trial conducted by Gharaei et al,35 AST administered at a dose of 8 mg significantly enhanced systemic antioxidant status, as reflected by markedly higher serum catalase (CAT) and total antioxidant capacity (TAC) levels compared with placebo, indicating a strong antioxidative effect of AST in PMOS patients. These findings are clinically relevant given the established role of oxidative stress in the pathophysiology of PMOS. The reproductive benefits of AST have also been demonstrated in subsequent trials. Jabarpour et al36 reported in a double-blind randomized study that supplementation with 12 mg/day of AST significantly increased the proportion of women achieving a normal menstrual cycle compared with baseline values, highlighting its potential role in improving menstrual regularity. Furthermore, in a blocked randomization study by Jabarpour et al,37 AST supplementation at 12 mg/day for 60 days was associated with a significantly higher rate of high-quality embryos compared with placebo. This improvement in embryo quality translated into better reproductive outcomes, as the AST group demonstrated a higher chemical pregnancy success rate (44.44%) than the control group. Collectively, these studies indicate that AST may help to improve oxidative balance, menstrual function, and assisted reproductive outcomes in women with PMOS, supporting its emerging role as a complementary therapeutic option in the management of PMOS-related infertility. The relevant findings are summarized in Table 3. Table 3Evidence for AstaxanthinAuthorStudy DesignKey Eligibility CriteriaInterventionSample SizeKey FindingsGharaei et al (2022)35Double-blind, randomized, placebo-controlled trialPCOSTest arm (8 mg AST)Control arm (Placebo)42AST supplementation showed significantly higher levels of serum CAT (8.22 ± 2.38) and TAC (0.599 ± 0.21) compared to the placebo arm (3.91 ± 2.61 and (0.398 + 0.20 respectively).Jabarpour et al (2024)36Double-blind randomized trialPCOSTest arm received 12 mg AST capsule and Control arm received placebo.56The results indicated that, normal menstrual cycle increased after AST therapy in the treatment arm compared to the baseline values (p = 0.031).Jabarpour et al (2023)37Blocked randomization studyPCOSThe patients were classified into ASTtreatment (receiving 12 mg/day for 60 days) and placebo groups.58The results indicated that the rate of high-quality embryos was significantly higher in the study group than in the control group (P < 0.05). Additionally, the AST group showed chemical pregnancy success rate of 44.44%, which was higher than the 34.61% success rate observed in the placebo group.Abbreviations: PCOS, polycystic ovarian syndrome; TAC, total antioxidant capacity; AST, astaxanthin; CAT, catalase. Evidence for Astaxanthin Abbreviations: PCOS, polycystic ovarian syndrome; TAC, total antioxidant capacity; AST, astaxanthin; CAT, catalase. Melatonin Recent research emphasizes the considerable role of melatonin as an adjunctive therapy for enhancing ovulation and fertility outcomes in women with PMOS, especially in the context of in vitro fertilization (IVF). Hosseini et al38 demonstrated that melatonin supplementation significantly reduced the number of poor-quality embryos compared with COS alone, with a trend towards higher biochemical and clinical pregnancy rates (P=0.089), suggesting an embryo-protective effect likely mediated through improved oocyte and embryo microenvironment. Supporting this concept, Khan et al39 observed significantly lower melatonin concentrations in follicular fluid associated with highly fragmented embryos in non-pregnant IVF patients, indicating that intra-follicular melatonin levels may be closely linked to embryo integrity and developmental competence. In women with PMOS, several randomized and prospective studies have shown that melatonin favorably modulates ovarian function and endocrine profiles. Pacchiarotti et al40 reported that the combination of melatonin with myo-inositol and folic acid resulted in the highest proportion of mature metaphase II oocytes compared with myo-inositol alone or folic acid alone, suggesting a synergistic role of melatonin in enhancing oocyte maturation and embryo quality. Similarly, Akter et al41 demonstrated that pretreatment with melatonin for eight weeks in infertile women with PMOS significantly reduced serum testosterone, luteinizing hormone levels, insulin resistance, and impaired glucose tolerance, while also improving follicular development and endometrial thickness when compared with letrozole-based ovulation induction alone. The anti-androgenic, anti-inflammatory, and antioxidant effects of melatonin have been consistently reported. In a double-blind, placebo-controlled trial, Jamilian et al42 showed that 12 weeks of melatonin supplementation significantly reduced hirsutism scores, total testosterone, high-sensitivity C-reactive protein, and malondialdehyde levels, while markedly increasing total antioxidant capacity and glutathione concentrations in women with PMOS. These findings support melatonin’s role in mitigating oxidative stress and chronic low-grade inflammation, which are central to PMOS pathophysiology. Complementing these results, Tagliaferri et al43 reported that six months of melatonin therapy in women with PMOS led to significant reductions in androgen levels, increased follicle-stimulating hormone concentrations, and improved menstrual regularity in many participants. Mousavi et al44 found that melatonin alone or in combination with magnesium significantly reduced serum tumor necrosis factor-α levels, with the combined regimen producing the greatest improvement in antioxidant capacity, further underscoring melatonin’s immunomodulatory and antioxidative properties. Detailed information regarding this aspect is provided in Table 4. Table 4Evidence for MelatoninAuthorStudy DesignKey Eligibility CriteriaInterventionSample SizeKey FindingsHosseini et al (2021)38A single-blindnonrandomized controlled trialInfertile couplesMelatonin as supplementation to the standard COS. The control arm received the COS protocol only.90The mean number of poor-quality embryos was significantly lower in the intervention arm than that in the control arm (0.27 vs 0.80; P = 0.028). The biochemical and clinical pregnancy rates were higher in the intervention arm (24% vs 14%, P = 0.089, and 14% vs 7%, P = 0.302, respectively).Pacchiarotti et al (2015)40Randomized studyPCOSControls received only folic acid (400 mcg), Group A (study group) MI (4000 mg), folic acid (400 mcg) and M (3 mg) and Group B MI (4000 mg) and folic acid (400 mcg) gonadotropin IU administered, serum estradiol (hCG) administration.569The proportion of mature oocytes at the metaphase II stage was highest in Group A (48.2%) relative to Group B (35.0%) and the control group (38.2%), indicating that melatonin may synergistically enhance oocyte and embryo qualityAkter et al (2023)41Randomized studyInfertile with PCOSIntervention arm received melatonin 3 mg at bedtime for 8 weeks as Pretreatment Intervention arm continued melatonin until mature follicle achieved.Control arm received ovulationinduction by letrozole.74Melatonin treatment for 8 weeks significantly decreased testosterone (P <0.01), serum LH (